An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis

NCT ID: NCT00896168

Last Updated: 2013-09-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 234 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-06-30
• Study Completion Date: 2008-04-30

Brief Summary

The purpose of this study is to compare the effectiveness of iInfliximab plus methotrexate (MTX) in treatment of Rheumatoid rheumatoid Arthritis arthritis (RA) (it is an autoimmune disease that causes pain, swelling, stiffness and loss of function in joints) in participants with moderate disease versus participants with severe disease and to compare the efficacy and safety of the MTX subgroups.

Detailed Description

This is an open-label (all people know the identity of the intervention), multi-center (study conducted in more than 1 center), prospective (study following participants forward in time) study comparing the American College of Rheumatology (ACR) scores of participants with moderate RA (defined as having a score greater than 3.2, but less than 5.1 on the Disease Activity Score 28 [DAS 28]) to those participants with severe RA (defined as having a score greater than 5.1 on the DAS 28 score) disease while being treated with infliximab and MTX. DAS evaluates RA activity by several parameters including the number of swollen and tender joints and the participant's own assessment of their pain. Participants will receive infliximab 3 milligram (mg) per kilogram (kg) intravenous infusion (drug given into a vein) (over no less than 2 hours) at Weeks 0, 2, 6, 14 and 22 along oral MTX in a stable dose of 7.5 to 20 mg per week (equal to the dose used before participation in the study) for 22 Weeks. Participants will have a follow-up visit on Week 26. Efficacy will primarily be assessed by the percentage of participants obtaining ACR20, ACR50 and ACR70 response at Week 26. Participants' safety will be assessed throughout the study.

Conditions

Arthritis, Rheumatoid

Keywords

Arthritis, Rheumatoid; Infliximab; Methotrexate

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Infliximab + Methotrexate (Moderate RA)

Participants with moderate RA (score greater than 3.2, but less than 5.1 on the disease activity score \[DAS\] 28) received infliximab 3 milligram per kilogram (mg/kg) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) at Week 0, 2, 6, 14 and 22 along with oral MTX IN a stable dose of 7.5 to 20 mg per week (equal to the dose used before participation in the study) for 22 weeks.

Group Type: EXPERIMENTAL

Infliximab

Intervention Type: DRUG

Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.

Methotrexate

Intervention Type: DRUG

MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.

Infliximab + Methotrexate (Severe RA)

Participants with severe RA (score greater than 5.1 on the DAS 28) received infliximab 3 mg/kg intravenous infusion at Week 0, 2, 6, 14 and 22 along with oral MTX in a stable dose of 7.5 to 20 mg per week (mg/week) equal to the dose used before participation in the study) for 22 weeks.

Group Type: EXPERIMENTAL

Infliximab

Intervention Type: DRUG

Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.

Methotrexate

Intervention Type: DRUG

MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.

Interventions

Infliximab

Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.

Intervention Type: DRUG

Methotrexate

MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participants who have a definitive diagnosis of rheumatoid arthritis (RA) based on the American College of Rheumatology Criteria 1987
• Participants must have been on Methotrexate (MTX) for 12 weeks at the stable dose for at least 4 weeks
• Participants using oral corticosteroids, must have been on a stable dose of prednisone less than 10 milligram per day (mg/day) or its equivalent for at least 4 weeks before screening or if currently not using corticosteroids, the participant must not have received corticosteroids for at least 4 weeks before screening
• Participants with moderate to severe RA (Disease Activity Score [DAS28] greater than 3.2)
• Male participants shall adopt contraceptive measures during the trial and within 6 months after the completion of trial (such as spermicidal barrier), or their female sexual partners shall agree to adopt effective contraceptive measures during the trial or within 6 months after the completion of trial (such as oral contraceptives, contraceptives for injection, intrauterine device [IUD], or sterilization by surgery); female participants of childbearing potential with negative urine pregnancy test upon enrollment in addition to adopting the said contraceptive measures

Exclusion Criteria

• Participant who has a known allergy to human immunoglobulin proteins or other components of infliximab
• Participant who has a history of receiving infliximab or any other biological preparations
• Participant who is in stage IV RA evaluated by X-ray
• Participants suffering from tuberculosis
• Female participant or male participant's wife who plans to become pregnant during this study and within 6 months after completion of this study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xian-Janssen Pharmaceutical Ltd. Clinical Trial

Role: STUDY_DIRECTOR

Xian-Janssen Pharmaceutical Ltd.

Other Identifiers

REMICADEART4005

Identifier Type: -

Identifier Source: secondary_id

CR015460

Identifier Type: -

Identifier Source: org_study_id